姬燕晓 特聘研究员

职称职务： 特聘研究员

学科专业： 病理生理学

研究方向：翻译后修饰与代谢性疾病机制

实验室位置：基础医学院3号楼613、615

Email： jiyanxiao@whu.edu.cn

学习经历

2005.9~2009.6 成都理工大学 材化院 生物工程 本科

2009.9~2015.7 武汉大学 生命科学学院 遗传学 博士

主要工作经历与任职

2015.8~2017.6 武汉大学 基础医学院 博士后

2017.7~2021.7 武汉大学中南医院 助理研究员

2021.8~今 武汉大学 基础医学院 特聘研究员

目前主要科学研究领域和兴趣

蛋白质翻译后修饰交互调控网络在代谢紊乱中的作用机制

基于靶点的抗体、小分子药物研发

代表性论文（近5年，10篇以内的第一作者或通讯作者论文）

1) Ji YX#*, Wang YT#, Li PL#, Cai L#, Wang XM, Bai L, Liu Z, Tian H, Tian S, Zhang P, Zhang XJ, Cheng X, Yuan YF, She ZG*, Li H*. (2021). A kinome screen reveals that Nemo-like Kinase is a key upstream regulator of hepatic gluconeogenesis. Cell Metabolism.33: 1-16

2) Wang J#, Ma J#, Nie H#, Zhang XJ, Zhang P, She ZG, Li H*, Ji YX*, Cai J*. (2020). Hepatic Regulator of G protein Signaling 5 Ameliorates NAFLD by Suppressing TAK1-JNK/p38 Signaling. Hepatology. 73(1):104-125.

3) Zhang L#, Tian R#, Yao X#, Zhang XJ, Zhang P, Huang Y, She ZG, Li H*, Ji YX*, Cai J*. (2020). Milk Fat Globule–Epidermal Growth Factor–Factor 8 Improves Hepatic Steatosis and Inflammation. Hepatology. 73(2):586-605.

4) Cheng X#, Liu Y-M#, Li H#, Zhang X#, Lei F#, Qin J-J, Chen Z, Deng K-Q, Lin L, Chen M-M, Song X, Xia M, Huang X, Liu W, Cai J, Zhang X-J, Zhou F, Zhang P, Wang Y, Ma X, Xu Q, Yang J, Ye P, Mao W, Huang X, Xia J, Zhang B-H, Guo J, Zhu L, Lu Z, Yuan Y*, Wei X*, She Z-G*, Ji YX*, Li H*. (2020). Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metabolism. 32(4): 537-547.

5) Bai L#, Chen MM#, Chen ZD#, Zhang P, Tian S, Zhang Y, Zhu XY, Liu Y, She ZG, Ji YX*, Li H*. (2019). F-box/WD Repeat-Containing Protein 5 Mediates the Ubiquitination of Apoptosis Signal-Regulating Kinase 1 and Exacerbates Nonalcoholic Steatohepatitis in Mice. Hepatology. 70(6):1942-1957.

6) Fang J#, Ji YX#, Zhang P#, Cheng L, Chen Y, Chen J, Su Y, Cheng X, Zhang Y, Li T, Zhu X*, Zhang XJ*, Wei X*. (2019). Hepatic IRF2BP2 Mitigates Nonalcoholic Fatty Liver Disease by Directly Repressing the Transcription of ATF3. Hepatology. 71(5):1592-1608.

7) Ji YX#, Huang Z#, Yang X#, Wang X#, Zhao LP, Wang PX, Zhang XJ, Alves-Bezerra M, Cai L, Zhang P, Lu YX, Bai L, Gao MM, Zhao H, Tian S, Wang Y, Huang ZX, Zhu XY, Zhang Y, Gong J, She ZG, Li F, Cohen DE*, Li H*. (2018). The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis. Nature Medicine. 24(2): 213-223.

8) Wang PX#, Ji YX#, Zhang XJ#, Zhao LP, Yan ZZ, Zhang P, Shen LJ, Yang X, Fang J, Tian S, Zhu XY, Gong J, Zhang X, Wei QF, Wang Y, Li J, Wan L, Xie Q, She ZG, Wang Z, Huang Z, Li H*. (2017). Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates. Nature Medicine. 23(4): 439-449.

9) Ji YX#, Zhang P#, Zhang XJ#, Zhao YC, Deng KQ, Jiang X, Wang PX, Huang Z, Li H*. (2016). The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signalling. Nature Communications. 7: 11267.

10) Deng KQ#, Wang A#, Ji YX#, Zhang XJ, Fang J, Zhang Y, Zhang P, Jiang X, Gao L, Zhu XY, Zhao Y, Gao L, Yang Q, Zhu XH, Wei X, Pu J*, Li H*. (2016). Suppressor of IKKvarepsilon is an essential negative regulator of pathological cardiac hypertrophy. Nature Communications. 7: 11432.